Skip to content

Our Team

We help you turn your dream into reality

US

Theresa Heah, an accomplished leader in the biotech industry, has over two decades of global experience in spearheading the development and commercialization of innovative therapies. She most recently served as CEO, President, and Board Member at Intergalactic Therapeutics (an Apple Tree Partners company).

Her career spans in the core business area from small molecules to biologics to gene therapies development, and commercialization in early-stage private-staged companies (Fovea Pharmaceuticals acquired by Sanofi, AsclepiX Therapeutics, Kriya Therapeutics), public-staged (Aerie Pharmaceuticals acquired by Alcon, Allergan acquired by AbbVie, AGTC (acquired by Syncona, rebranded as Beacon Therapeutics) and big pharmaceuticals (Bayer Healthcare, Sanofi).

With a diverse background spanning small molecules, biologics, and gene therapies, Theresa has navigated successful M&A deals, venture capital fundraising, and the launch of groundbreaking products in various therapeutic areas including ophthalmology, oncology and CNS. Her achievements include multiple global regulatory approvals in the U.S., Europe, Japan for revolutionary therapies like Ozurdex, EYLEA, Rhopressa, and Rocklatan.

Theresa holds a medical degree from King’s College, University of London, and an Executive MBA from the European School of Management & Technology (ESMT), Berlin.

Back To Top
Search